Abzena plc, a life sciences Group providing services and technologies that enable the development and manufacture of biopharmaceutical products, notes the announcement today of the acquisition by Roche of Adheron Therapeutics (“Adheron”).
Adheron was a privately held biotechnology company developing SDP051, a product that disrupts cell adhesion which can potentially be used to treat inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic disease. SDP051 was fully humanised using Abzena’s Composite Human Antibody™ technology.
Adheron has completed a Phase I study of SDP051 and the product was shown to be safe and well-tolerated. Further development of SDP051 will be pursued by Roche.
SDP051 is one of Abzena’s portfolio of ten clinical-stage Composite Human Antibodies being developed by the Group’s partners. Abzena has a significant portfolio of licence and licence option agreements covering these products with many more being evaluated in research programmes and in preclinical development.
Source: Abzena